<DOC>
	<DOCNO>NCT00881387</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cell-killing substance . Drugs use chemotherapy , gemcitabine vinorelbine , work different way stop growth cancer cell , either kill cell stop divide . Giving rituximab together gemcitabine vinorelbine may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together gemcitabine vinorelbine work treat patient Hodgkin lymphoma relapse responded treatment .</brief_summary>
	<brief_title>Rituximab , Gemcitabine , Vinorelbine Treating Patients With Hodgkin Lymphoma That Has Relapsed Not Responded Treatment</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess response rate ( complete response/remission , unconfirmed complete response , partial response/remission ) patient relapse refractory Hodgkin lymphoma treat 3 course rituximab , gemcitabine hydrochloride , vinorelbine ditartrate . Secondary - Assess progression-free survival , failure-free survival , overall survival patient treat regimen . - Characterize safety profile regimen patient . - Determine rate adequate stem cell collection ( ≥ 2 million CD34+ cell ) patient eligible stem cell transplantation . OUTLINE : Patients assign 1 2 treatment group accord eligibility stem cell transplantation ( SCT ) . - Group 1 ( eligible SCT ) : Patients receive rituximab IV , vinorelbine ditartrate IV 6-10 minute , gemcitabine hydrochloride IV 30 minute day 1 pegfilgrastim subcutaneously day 2 . Treatment repeat every 14 day 3 course absence disease progression unacceptable toxicity . Patients complete response ( CR ) partial response ( PR ) undergo SCT . - Group 2 ( ineligible SCT ) : Patients receive rituximab , vinorelbine ditartrate , gemcitabine hydrochloride , pegfilgrastim group 1 . Patients CR , PR , stable disease 3 course continue receive therapy absence disease progression unacceptable toxicity . After completion study therapy , patient follow least 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm classical Hodgkin lymphoma , include 1 follow cell type : Nodular sclerosis Mixed cellularity Lymphocyterich Lymphocytedepleted Measurable disease use Cheson criterion , define ≥ 1 unidimensionally measurable lesion ≥ 2.0 cm conventional technique OR ≥ 1.0 cm spiral CT scan Progressive relapse disease ≥ 1 prior line combination chemotherapy No known CNS metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 ANC &gt; 1,500/mm^3 Platelet count &gt; 75,000/mm^3 Total bilirubin ≤ 2 mg/dL ( unless due hemolysis ) AST ALT ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active hepatitis B infection No known chronic hepatitis B carrier No HIV positivity No concurrent uncontrolled illness include , limited , follow : Symptomatic neurological illness Active uncontrolled systemic infection consider opportunistic , lifethreatening , clinically significant time study treatment Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Significant pulmonary disease hypoxia Psychiatric illness social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : See Disease Characteristics More 14 day since prior chemotherapy , immunotherapy , biological therapy , investigational therapy recover No prior gemcitabine hydrochloride , vinorelbine ditartrate , rituximab No concurrent investigational commercial agent therapy intent treat malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte predominant Hodgkin lymphoma</keyword>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
</DOC>